Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street an­a­lysts that cov­er Sarep­ta $SRPT are an up­beat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or of­fer ex­pla­na­tions when an odd set­back oc­curs — as hap­pened re­cent­ly with a safe­ty sig­nal that was ‘er­ro­neous­ly’ re­port­ed last week.

Ritu Bar­al Cowen

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER